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RNA expression profiles are increasingly used to diag-
nose and classify disease, based on expression patterns
of as many as several thousand RNAs. To ensure quality
of expression profiling services in clinical settings, a
standard operating procedure incorporates multiple
quality indicators and controls, beginning with preana-
lytic specimen preparation and proceeding thorough
analysis, interpretation, and reporting. Before testing,
histopathological examination of each cellular speci-
men, along with optional cell enrichment procedures,
ensures adequacy of the input tissue. Other tactics in-
clude endogenous controls to evaluate adequacy of RNA
and exogenous or spiked controls to evaluate run- and
patient-specific performance of the test system, respec-
tively. Unique aspects of quality assurance for array-
based tests include controls for the pertinent outcome
signatures that often supersede controls for each indi-
vidual analyte, built-in redundancy for critical analytes
or biochemical pathways, and software-supported scru-
tiny of abundant data by a laboratory physician who
interprets the findings in a manner facilitating appro-
priate medical intervention. Access to high-quality re-
agents, instruments, and software from commercial
sources promotes standardization and adoption in clin-
ical settings, once an assay is vetted in validation studies
as being analytically sound and clinically useful. Careful
attention to the well-honed principles of laboratory
medicine, along with guidance from government and
professional groups on strategies to preserve RNA and
manage large data sets, promotes clinical-grade
assay performance. (J Mol Diagn 2012, 14:1–11; DOI:
10.1016/j.jmoldx.2011.09.003)
Microarray technology and RNA signatures have a long
and somewhat rocky track record in basic science labo-ratories. In the past few years, advances in technology
and quality assurance suggest that genomic profiling is
reliable enough for medical decision making in clinical
trials and ultimately in routine patient care. Factors con-
tributing to adoption in clinical settings include the follow-
ing: i) good manufacturing practices for reagents, sup-
plies, control instruments, and software; ii) progress in
biospecimen science that promotes RNA integrity; iii)
advances in bioinformatics, facilitating interpretation of
complex data; and iv) novel strategies for quality control,
ensuring that each patient test performs as expected.
Microarrays permit measurement of hundreds or even
tens of thousands of RNAs simultaneously, including
coding and noncoding RNAs of human and microbial
sources.1 RNA profiles that are unique to clinical status
can assist with diagnosis, prognosis, monitoring, and
predicting efficacy of therapy. To warrant adoption in
clinical settings, the assay must provide added value
beyond what is already available to patients or their
health care system.2
RNA profiling is guided by high standards and well-
honed principles of laboratory medicine that ensure qual-
ity while allowing innovation and progress. The quality
systems that are being adapted to expression profiling
are emblematic of the novel strategies being developed
to manage a wide range of multianalyte technologies,
such as full-genome sequencing, proteomics, and sin-
gle-nucleotide polymorphism chips. The two most impor-
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sonnel to perform each assay and controls and quality
indicators that help these personnel identify and correct
problems.3 Meticulous attention to detail, expert techni-
cal knowledge, and medical judgment are required to
validate and maintain each assay. During validation work,
a standard operating procedure is refined and tested,
and evidence is collected to substantiate choices regard-
ing specimen requirements, indications for testing, rec-
ommended clinical use of test results, step-by-step anal-
ysis, and quality control processes.4–6 Each new assay
or modification to an assay must be vetted by the labo-
ratory director as being analytically sound and clinically
useful enough to justify implementation as a medical ser-
vice. This article reviews the quality assurance measures
that are established during assay validation and that are
used on a daily basis to ensure good outcomes.
Governmental Oversight of Laboratory Services
in the United States
Scrupulous attention to detail and high standards ensure
the quality of laboratory work performed in clinical set-
tings. Governmental oversight of testing laboratories, and
of the manufacturers providing reagents or test systems
to such laboratories, is codified in federal regulations of
the Clinical Laboratory Improvement Amendments and
Title 21, directing the Food and Drug Administration
(FDA). Many RNA-based assays have been FDA cleared
or approved, such as tests to detect HIV, hepatitis C
virus, mycobacterium tuberculosis, and influenza virus.
Quantitative RT-PCR (RT-qPCR) is the technology most
frequently used in clinical molecular laboratories, and
panels of RT-qPCRs can reasonably be performed on
dozens to thousands of different analytes at once.7,8
For human gene discovery research, even denser ar-
rays provide expression data on virtually all (approxi-
mately 22,000) human protein-coding genes and
1000 microRNAs.1,9
To date, 10 multianalyte RNA assays have been FDA
cleared on Agilent (Santa Clara, CA), Affymetrix (Santa
Clara, CA), RT-qPCR, and bead-type platforms. These
include Mammaprint (Agendia, Irvine, CA) to help man-
age selected breast cancer patients,10,11 Tissue of Origin
Test (Pathwork Diagnostics, Redwood City, CA) to help
pathologists refine the type of malignancy,12 AlloMap
blood test for acute cellular rejection of a transplanted
heart (XDx, Brisbane, CA), BLN assay for breast tumor
metastasis to lymph nodes (Veridex, Raritan, NJ; this
assay was voluntarily withdrawn from the US market), and
six respiratory virus panels from Idaho Technologies (Salt
Lake City, UT), Nanosphere (Northbrook, IL), Applied
Biosystems (Carlsbad, CA), Focus Diagnostics (Cypress,
CA), Gen-Probe (San Diego, CA), and Luminex (Toronto,
ON, Canada). After approval of a predicate in vitro diag-
nostic device, the FDA often issues guidance for manu-
facturers validating similar assays. Many laboratory-de-
veloped tests have been implemented as medical
services under Clinical Laboratory Improvement Amend-
ment regulations, and examples of such laboratory-de-veloped tests characterizing RNA are BCR-ABL1 in leu-
kemia13 and Genomic Health’s (Redwood City, CA)
Oncotype Dx assay in breast cancer.14
The MicroArray Quality Control project began as an
initiative to assess the quality of RNA-based microarray
expression profiles and to recommend improvements.
The project was launched by the FDA and involves nearly
200 academic institutions, commercial manufacturers,
and governmental divisions. In work to date, sample ex-
changes and data set analyses showed that expression
profiling is technically robust, is biologically informative,
and generates similar profiles across multiple platforms
when viewed by functional means.15–18 Several ap-
proaches to prediction modeling were deemed effec-
tive.15,19 The European Union’s EMERALD project (Em-
powering the Microarray-Based European Research
Area to Take a Lead in Development and Exploitation)
developed software tools for quality metrics of array
data.20
Guidance from Professional Groups
Several laboratory professional groups offer guidance on
clinical-grade procedures and standards. In particular,
checklists marketed by the College of American Pathol-
ogists (CAP) as part of their worldwide laboratory accred-
itation program are a blueprint for achieving good out-
comes (http://www.cap.org, see Reference Resources
and Publications section of website; last accessed June
30, 2011). The Clinical and Laboratory Standards Insti-
tute produces documents thoroughly describing princi-
ples and best practices, such as Diagnostic Nucleic Acid
Microarrays,21 Verification and Validation of Multiplex Nu-
cleic Acid Assays,22 and Use of External RNA Controls in
Gene Expression Assays.23 Three European organiza-
tions developed joint guidelines for microarray profiling of
leukemia,24 and most of the recommended principles
and procedures extend to other diseases.
Some multiplexed tests target thousands of RNAs at
once, although the minimum number of analytes com-
posing an array is only 11, according to the American
Medical Association Current Procedural Terminology
Editorial Panel. In the United States, reimbursement by
payers for microarray services is accomplished using
the physician fee schedule, emphasizing that a pathol-
ogist or other laboratory physician is responsible for
technical work and uses medical judgment in expert
interpretation of the findings. Among the many require-
ments of Clinical Laboratory Improvement Amendment
certification is that a physician consultant be available
to discuss indications for testing and patient-specific
result interpretation for all tests offered by high-com-
plexity clinical laboratories.
Preanalytic Specimen Preparation
Preanalytic collection, stabilization, transport, and stor-
age conditions are critical for obtaining accurate analytic
test results.25–29 Interestingly, procedures that may seem
irrelevant can affect outcome, such as first versus second
pass of a needle-core biopsy30 or freezing of blood or
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dresses these preanalytic concerns.33,34 The testing lab-
oratory takes a trust-and-verify approach by educating
health care workers in proper collection and handling
procedures, while using quality checks, such as house-
keeping transcript levels, to evaluate specimen quality.
RNA is notorious for rapidly degrading if special pre-
cautions are not taken to preserve it.33,35 In stored blood
and marrow, Ma et al36 showed similar RNA profiles for
frozen versus TRIzol-preserved cells. Stabilization of RNA
at the bedside is feasible using commercial blood col-
lection systems that must be validated for their intended
use.37–42 The advantages of RNA stability must be
weighed against the cost of stocking special collection
vials at every pertinent blood collection site and the in-
capacity to interpret smears or apply cell enrichment
procedures once the preservative is added.
For solid tissue, 10% neutral-buffered formalin is the
fixative favored by nearly all histopathology laboratories.
Formalin functions by aldehyde cross-linking to generate
a scaffold preventing tissue degradation and diminishing
unwanted enzymatic activity (eg, RNases). Diffusion of
formalin into tissue is a function of distance and density;
thus, slicing tissue into thin pieces promotes rapid fixa-
tion. The duration of fixation is critical, with sufficient time
required to ensure adequate preservation of analytes,
while avoiding overfixation that hardens tissue and in-
creases cross-links with macromolecules, rendering in-
tact RNA difficult to recover.43–45 A study by Chung et
al46 showed that fixation between 4 and 48 hours was
reasonable, although 12 to 24 hours was ideal with re-
spect to downstream RNA quality. Incubating RNA in
warm Tris buffer is predicted to reverse, at least in part,
the adverse effects of formalin.45 In validation work, con-
sider splitting fresh specimens and testing pertinent pre-
analytic variables to gather the evidence required to set
limits on acceptable specimen preparation for the partic-
ular assay.47,48
Fresh or frozen tissue tends to have much better-qual-
ity RNA than does formalin-fixed tissue, but formalin-fixed
tissue is readily available in clinical settings and, thus, is
the specimen of choice. Acid decalcification is not rec-
ommended because depurination fragments nucleic
acid. Alternative fixatives, particularly alcohol-based so-
lutions, often yield high-quality RNA,49–51 but these fixa-
tives may suffer when rated by pathologists for histolog-
ical detail, not to mention the adverse impact on
immunostains and other histochemical procedures that
are frequently applied in clinical settings.52 It appears
that a molecular test is most likely to be adopted if the test
is robust enough to work on customary specimens, rec-
ognizing that the term customary encompasses a wide
range of nonstandardized formalin fixation protocols.47
Fortunately, multiple groups53–55 have succeeded in pro-
filing RNA from archival formalin-fixed tissues. Because
some, but not all, target RNA levels are equivalent in
paraffin blocks versus matched frozen tissue,56–61 it is
clear that each RNA-based test must be validated for its
relevant specimen preparation.Enrichment of Lesional Cells
To generate an accurate RNA signature, the input tissue
must be appropriately representative of the organ or le-
sion being evaluated.62 To accomplish this, a pathologist
examines a stained slide to confirm histopathological
findings and to assess tissue adequacy for the particular
test.63 If indicated, lesional cell enrichment is done by ma-
crodissection or microdissection.64–66 For blood, marrow,
or other cytologic fluids, cell enrichment is achieved using
flow cytometry or magnetic bead separation.67 For plasma
or serum, variations in the protocol for cell separation can
affect downstream RNA measurement.68,69
Criteria for tissue selection are defined during valida-
tion work. In tumor profiling, the amount and nature of the
malignant and stromal cell components can influence the
profile, depending on which RNAs compose the test
panel, the anatomical site (eg, primary versus meta-
static), and whether the stroma is normal, fibrotic, des-
moplastic, or inflammatory.62,70 In preanalytic work, a
pathologist typically selects a portion of tissue in which
malignant cell nuclei exceed a given proportion of all
nuclei present, which is different from circling malignant
areas because those areas might contain only scattered
malignant cells in a sea of reactive stromal cells. Expert
interpretation of downstream molecular results is done in
the context of the input tissue and other correlative data.
RNA Extraction and Quantification
In busy clinical laboratories, automated RNA extraction
instruments help control costs and improve reproducibil-
ity. Staal et al24 reported that the extraction method
(TRIzol versus RNeasy) affects RNA expression patterns
in blood, providing cautionary evidence that substituting
extraction protocols can adversely affect results. Skip-
ping extraction altogether is feasible for some robust
technologies.71,72
It is often worth evaluating RNA quantity and quality
before subjecting a specimen to expensive microarray
analysis. RNA concentration is measurable by UV spec-
trophotometry or fluorimetry, and RNA size distribution
may be visualized on an electropherogram and scored
using a software algorithm (eg, RNA integrity score).73
The spectrum of RNA size is dramatically larger in fresh
or frozen tissue compared with formalin-fixed, paraffin-
embedded tissue (Figure 1). A 1-hour delay in fresh
specimen processing does not adversely affect the RNA
integrity score, although it may disturb individual ana-
lytes.52,74,75 By RT-qPCR, amplicons 500 bp are infre-
quently achieved from formalin-fixed tissues compared
with frozen tissue, and RNA integrity scores do not pre-
dict amplifiability from paraffin tissue blocks; instead, lev-
els of housekeeping transcripts, and separate hybridiza-
tions of 5= and 3= ends of such transcripts, are helpful for
assessing specimen quality.58 The usual precautions to
protect RNA are in order, such as use of RNase-free
reagents and plasticware, wearing and frequently chang-
ing gloves, and keeping a clean work environment by
wiping surfaces with 10% bleach or RNase ZAP (Ambion)
and using disposable bench covers.
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Quality control is among the most important of quality
assurance measures.3 Although traditional single-analyte
assays require inclusion of a positive and a negative
control in every run, it is clear that microarray runs cannot
possibly include controls for each of the dozens to thou-
sands of target analytes, not to mention the impossibility
of representing each of the permutations and combina-
tions of expressed genes that might be found in a given
specimen. Thus, a new paradigm of quality control has
emerged to accommodate multianalyte arrays.76 In short,
the approach engenders confidence that the pattern of
expression is accurate and reproducible.
Controls are used to check assay performance, with
special focus on the least robust components. Multiple
types of controls are used in RNA profiling. A “no tem-
plate” control can evaluate background signal and con-
tamination by stray nucleic acid. An exogenous control is
run alongside patient specimens to evaluate assay per-
formance in a general manner. A separate exogenous
control, representing each of the main outcome groups,
could be included for every X patients who are run, with
X chosen based on the medical impact of an erroneous
classification and the timeliness required to correct any
error, recognizing that failure of a control will launch an
Figure 1. Agilent Bioanalyzer electropherograms reflect RNA size spectrum.
A: Intact RNA from frozen tissue has prominent 18S and 28S rRNA peaks
surrounded by other relatively large RNA molecules. B: Degraded RNA from
matched paraffin-embedded tissue has much smaller RNA fragments and a
lower RNA integrity (RIN) score.investigation that questions the results for those patientstested since the last time that the control performed as
expected.
An endogenous control checks an inherent feature of
patient sample, such as a housekeeping transcript,
which is particularly valuable for assessing preanalytic
factors (eg, viable cellularity, collection, preservative,
shipping, and storage). Because of inherent biological
variability in levels of any given gene product, it is rec-
ommended to identify several housekeepers that are
consistently expressed at low to high levels in the rele-
vant tissue or fluid. Adequate expression of these house-
keepers reflects suitable hybridizable RNA, thus permit-
ting rejection of poor-quality specimens or those with
faulty technical analysis. In addition, housekeepers can
serve as a normalizer by which to quantify target
RNAs.73,77–79 Caution is warranted because ex vivo deg-
radation proceeds at different rates for different analytes,
reinforcing the need to validate the control and normal-
ization strategy to promote comparability of results
across specimens.
Spiked controls are yet another way of checking assay
performance. Thanks to the work of the External RNA
Controls Consortium, commercial RNA standards are
newly available to assess technical accuracy.80,81 These
nonhuman, nonpathogen, spiked RNA products are mar-
keted [by Invitrogen (Carlsbad, CA) and VWR (Radnor,
PA)] as mixes of multiple synthetic RNAs at a known
concentration and a known sequence. They are spiked
into each patient specimen at the earliest informative time
point (eg, with lysis buffer) to permit downstream evalu-
ation of assay performance within the patient specimen.
Results can detect technical failure and iatrogenic inhi-
bition (eg, residual phenol or heparin anticoagulant) or
endogenous interfering substances (eg, hemoglobin or
background autofluorescence). Finally, combinations of
spiked molecules are proposed as a way of tracking
specimen identity through the many steps of specimen
preparation and analysis.82
Limits on acceptable performance of controls are em-
pirically set by replicate analysis. Consider running a
control many times (across different days, technologists,
instruments, and lot numbers), and then calculate the
mean  2 SDs as the limit on its performance. When
multiple controls are used, the expected failure rate in-
creases accordingly. For example, a failure rate of 5% for
any one control implies that a combination of four controls
will fail 18% of the time. This high failure rate emphasizes
the benefits of a quality control strategy that includes
multiple controls for the many critical aspects of the as-
say and synthesizes multiple data points to interpret over-
all success or failure of an assay.
Control results falling outside acceptable limits are
documented and investigated for root cause and, when
feasible, to take corrective action. When combined with
quality indicators (eg, spectrophotometry or histopatho-
logical characteristics), results of controls can help pin-
point the source of the problem. Affected patient tests are
usually repeated, when sufficient specimen remains. Re-
cords of problems, investigations, and potential solutions
are fodder for the laboratory’s quality improvement
program.
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Exogenous controls should resemble patient specimens.
Human tissue remaining after clinical analysis can be
fractionated and stored for use as a control, although
some heterogeneity is expected across aliquots. Xeno-
grafts are an alternative source of abundant human cells,
although contamination with cells of the host species
merits study to show that the xenograft is sufficiently
representative of the RNA profile of interest. Fresh blood
controls are particularly hard to find, so it is reasonable to
use stored white cell pellets or residual RNA or cDNA
from previously tested specimens.
A mock specimen may be prepared by mixing a cell
line or RNA derived from that cell line with appropriate
matrix, and serial dilutions can be used to challenge
analytic sensitivity or linearity. Some lot-to-lot variation is
expected even when precise criteria are defined for cell
culture and harvest. Some scientists favor a mixture of
several cell lines to fill in gaps that an individual cell line
might have (eg, nonexpressed genes). This approach is
exemplified by the Agilent/Stratagene reference RNA
manufactured from a mixture of 10 cell lines and well
characterized by virtue of its analysis in multiple quality-
assurance studies.16,83,84
Single-use aliquots prevent multiple freeze-thaw cy-
cles. When the same control material is used in multiple
runs, selected numeric results can be tracked over time
using Levey-Jennings charts to visualize drift or shift.85
Linear Amplification, Labeling, and Two-Color
Arrays
When RNA quantity is limited, linear preamplification can
boost the signal,58,64,86–89 and a label can be incorpo-
rated to permit downstream detection after hybridiza-
tion.84 Labeling efficiency can be checked before
hybridization.
In some hybridization strategies, a competitor RNA is
cohybridized with patient RNA in a two-color approach.90
Compared with one-color assays, two-color assays are
more expensive and arguably avoidably complex given
that MicroArray Quality Control project II studies91,92 con-
firm that both one- and two-color strategies perform well.
Although the merits and risks of various assay designs
can be debated, it is imperative to use the same assay
protocol in patient care that was vetted in validation
studies.
cDNA Preparation
Before cDNA preparation, DNA is usually removed using
DNase. The cDNA production is driven off random prim-
ers, oligo dT primers targeting poly A tails of mRNA, or
specific primers targeting each RNA. The preparation of
cDNA is among the most inconsistent features of RT-
qPCRs. Whether replicates are required for this or any
other step of analysis depends on the variability ob-
served during reproducibility experiments performed in
the validation study. In general, an assay that is so finicky
as to require replicate testing may not be reliable enoughfor clinical use.93 As a rule, significant differences in
expression pattern between two patients must largely
represent true biological differences rather than technical
error.
Equipment, Reagents, and Test Systems
Lessons learned in the early days of expression profiling
led to many improvements in the manufacturing of hard-
ware, reagents, supplies, and software-supporting ex-
pression profiling. Manufacturers are vital for supplying
testing laboratories with reliable products.94 Purchasing
decisions favor suppliers who comply with the FDA’s
medical device current good manufacturing practices
(http://www.fda.gov/MedicalDevices/DeviceRegulationand
Guidance/PostmarketRequirements/QualitySystemsRegulations,
last accessed June 30, 2011) or comparable Interna-
tional Standardization Organization systems (http://
www.iso.org/iso/iso_9000_essentials, last accessed June
30, 2011), promoting quality and consistency.95,96 Ide-
ally, users and manufacturers communicate so that sub-
stantial changes to the product are conveyed to users,
and performance of the product in users’ hands drives
improvement by the manufacturer. Even after extensive
vetting by a manufacturer, it remains incumbent on the
testing laboratory to ensure that each product performs
adequately for its intended use.
Hybridization
Although assay design-related error should have been
addressed during assay validation (eg, cross-reactivity,
secondary structure diminishing intended base pairing,
and competition), other systematic errors may crop up
after implementation (eg, defective lot number or instru-
ment). In addition to the error detection strategies previ-
ously addressed, consider designing redundancy into
the test system by targeting critical analytes numerous
times (eg, in different physical quadrants of the array or
by probing both ends of a given transcript). Likewise, one
could test multiple components of a critical biochemical
pathway, multiple markers of a critical phenotype, or mul-
tiple conserved segments of an RNA viral genome. These
scenarios capitalize on the array’s strength in multiplexed
testing.
Analytic Interpretation of Results
Analytic interpretation involves generating a reportable
result after first evaluating raw data or data generated
using decision-support tools, for each control and for the
patient at hand. As an example, acceptable input RNA for
Affymetrix profiling of paraffin-embedded tissue was de-
fined by Roberts et al56 as RNA that, by RT-qPCR, had an
endogenous ACTB 3=/5= ratio of 20, a CT 7 between
ACTB and the exogenous Agilent/Stratagene Universal
Reference RNA, and an endogenous 28s ribosomal RNA
CT 15. In our laboratory, quality indicators before Agi-
lent profiling are listed in Table 1. After hybridization, an
example of quality metrics used to vet Agilent array data
on frozen tissue is shown in Figure 2. For Affymetrix
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housekeeping genes (ideal, 1; good, 3); noise; scaling
factor (should be lower than three-fold); visual check of
image for bubbles, scratches, and grid alignment; homo-
geneity of hybridization and uniformity of background;
and percentage of genes detectable (25%).
Individual markers of critical importance may be cho-
sen as a quality check, such as ESR1 (estrogen receptor)
RNA expression in breast cancer compared with ESR1
protein that has been tested by immunohistochemistry
(IHC) on the same surgical specimen.97 Although it is
recognized that RNA and protein-based tests may be
discrepant for biological rather than technical reasons,
the frequency of such discrepancies can be determined
during validation studies to identify quality indicators that
raise a red flag to be weighed in concert with results of
other controls and quality checks.
When redundant assays are present on the array, rep-
licates are examined for consistency or to find problem-
atic variations.98 As an example, a highly proliferative
tumor (identified by visualizing mitotic figures during the
tissue selection phase) is expected to express prolifera-
Table 1. Example Quality Indicators on RNA Processed from
Frozen Tissue in Preparation for Expression Profiling
of Cancer
Quality
indicator Description
1 The tissue specimen is rejected if there are not at
least 30% malignant cells, as determined by a
pathologist using microscopy
2 The RNA specimen is rejected if either of the
following is true: A260/A280 is 1.8, as
determined using Nanodrop (Wilmington, DE)
spectrophotometry; or the RNA integrity no. is
6.5, as determined using an Agilent
Bioanalyzer 2100
3 The labeled cRNA is rejected if either of the
following is true based on results of Nanodrop
fluorometry: there is 10 g of amplified
labeled cRNA or specific activity is 8 pmol
Cy5/g labeled cRNA
Quality indicators and limits of acceptability must be established using
evidence gathered during validation studies for the particular test being
developed.
Figure 2. Quality metrics are displayed by Agilent feature extraction softw
microarray system. Acceptability limits might include uniform spatial distrib
nonuniform 5% (A); the dynamic range of expression exceeding five orde
across signal intensities (C); and spike-in RNA measurements being linear, with a slo
13 and processed signal 6 (D).tion markers on the array, thus confirming coordinated
expression of those phenotypic markers that instill confi-
dence in the array-based results.99
Data analysis is done in the context of a thorough
understanding of the technical strengths and weak-
nesses of the test system, based on prior experience
gathered during validation work and subsequent clinical
practice. Software is relied on to present data in a manner
that facilitates its interpretation.100 A typical standard op-
erating procedure for data analysis involves normaliza-
tion for background or housekeeping transcript abun-
dance, log transformation to aid in comparing numeric
results with those in the validation set, and graphic dis-
play of pertinent findings.77,78,101–104 Overmanipulation
of the data should be avoided.105
To categorize results in a given patient, a predictive
model may be applied that finds patterns across many
analytes, as facilitated by a single-sample predictor al-
gorithm.21,59,106–110 Grouping global patterns of gene
expression is a unique strength of RNA expression pro-
filing. A categorical assignment is typically accompanied
by a statistic (eg, Spearman’s correlation coefficient) rep-
resenting degree of confidence12 (Figure 3).
Computer-generated scores or predictors are checked
to ensure that they make sense after evaluating pertinent
raw data. Unsupervised clustering with a heat map den-
drogram visually displays results of a given patient along-
side results of a panel of known specimens, to help
confirm categorization of the patient into the pre-estab-
lished group that most closely shares its expression pro-
file.110 It is important to recognize the limitations of hier-
archical clustering, especially because the patient may
not belong to any of the pre-established groups. Exoge-
nous controls should be chosen to check categoriza-
tion at the most critical medical decision points, rather
than using only canonical examples that minimally
challenge the test system.
Clinical Interpretation and Reporting
Clinical interpretation is the process by which the medical
significance of the result is judged in light of the clinical
indication for which the test was ordered. Even if the end
sion 10.5.1.1) from a two-color gene expression experiment on an Agilent
ith local background of red and green signal 2% and numbers of features
gnitude (B); even distribution of significantly up- or down-regulated genes
2are (ver
ution, w
rs of mape 0.9, R  0.85, and replicate reproducibility signified by BGSubSignal
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score or a discrete disease classification, it is useful for
that result to be further interpreted in light of input tissue
characteristics; pertinent limitations of the assay, as re-
vealed by controls and quality checks (eg, specimen
thawed during transport and marginal housekeeping
RNAs recovered); and the level of confidence in the re-
sult. Furthermore, correlative analysis with other patient
information (eg, age, sex, tumor stage, IHC results, or
flow cytometric findings) paints a more complete picture
beyond the snapshot of expressed genes. More impor-
tant, the clinician deserves a clear message about impli-
cations for clinical decision making and recommended
follow-up. A report describing the BCR-ABL1 profile in a
newly diagnosed lymphoblastic leukemia could expound
Figure 3. Raw data are interpreted after evaluation of virtually all approxi-
mately 22,000 human protein-coding genes using Agilent microarrays. A: A
heat map shows gene expression profiles of 96 specimens tested for 50 listed
genes, and unsupervised hierarchical clustering reveals distinct patterns of
expression. B: To classify intrinsic subtypes of breast cancer, a single-sample
predictor algorithm compares each patient’s expression pattern with the
consensus pattern for each of the five intrinsic subtypes, and Spearman’s
correlation coefficients help estimate the certainty of the classification. In the
example shown, the patient’s profile matches most closely with luminal
(Lum) A, although Lum B subtype cannot be excluded, whereas three other
subtypes (normal, basal, and HER2) are excluded based on low correlation
coefficients.on the implications for response to tyrosine kinase inhib-itor therapy.111,112 Furthermore, follow-up testing by RT-
qPCR might be recommended to identify an amplifiable
translocation of BCR-ABL1 p210 or p190 that could be
serially measured as a biomarker of response during
therapy.112
To maximize the benefit of array-based testing, inter-
pretation by a physician who is expert in disease patho-
biological features and molecular technology is required.
This laboratory physician takes responsibility for the anal-
ysis and for the quality control processes that were used
in generating their interpretation. An experienced pathol-
ogist is capable of recognizing unusual or outlier results,
analogous to unforeseen results generated from histo-
pathological characteristics. For example, careful analy-
sis of RNA expression data may reveal erroneous soft-
ware-generated calls at variance with clinicopathological
findings. A melanoma tissue that was categorized into
good versus bad prognosis groups by a software algo-
rithm might, on closer inspection of raw data, lack the
typical melanoma markers, thus triggering investigation
of whether the patient has a look-alike tumor. Known
melanocyte markers that could be used in this evaluation
include MAGEA1, MITF, MART1 (melan-A), CMM
(HMB45), S100, and TYR (tyrosinase), each of which is
confirmable using IHC for the corresponding protein.
It is clear that medical judgment is required to identify
misleading data and to interpret the significance of find-
ings in light of evidence from patient records, published
literature, validation work, databases, and other reliable
sources.113 Pertinent results and interpretation are incor-
porated into a concise, yet informative, report that is
entered into the patient’s medical record. As described in
CAP guidelines for molecular test reporting,114 the doc-
ument should include a written summary of results and an
interpretation facilitating medical decision making. Re-
view of draft reports can help catch clerical errors. Re-
lated quality assurance tactics include periodic indepen-
dent appraisals, checking report format after electronic
transmission, and surveying client satisfaction.115
Data Set Retention
CAP suggests that patient test records be retained for at
least 2 years. The US federal regulations protect the
privacy of those records and require that the correspond-
ing procedure manual be retained, which serves to an-
notate each patient data set with the methods that were
used to generate it. When the full human transcriptome is
profiled, but only selected results are required for data
analysis and interpretation, software can then be pro-
grammed to mask irrelevant data. Later, one could mine
the same data set for the patient’s benefit, analogous to
re-examination of histopathological slides and blocks in
light of the following: i) refined criteria for microscopic
diagnosis, ii) availability of novel immunostains, iii) con-
cerns about accuracy, or iv) changes in clinical status.
Although RNA profiling might initially be used to help
make a diagnosis, later, the same data set could be
mined sequentially for prognosis and prediction of re-
sponse to first- and second-line therapies.
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Clinical laboratorians tend to choose methods that are
tried and true. It is, therefore, not surprising that clinical
laboratories are just now adopting expression profiling
after years of use and refinement in research set-
tings.116–118 RNA profiling is a complex process, and
each unique reagent, piece of equipment, or manual
action could be faulty. A principle of good assay design
is to restrict assay components to those that are safe (for
patients and health care workers) and simple, while still
meeting the clinical objective. Unlike in research settings,
turnaround time is critical, so the reliability of each assay
component is a key factor in the success of the medical
service. Translational research teams should include cli-
nicians who will order the test and act on test results,
technology experts who advise on platforms and re-
agents, and clinical laboratorians who will vet, perform,
and interpret test results.
The transfer of a specimen or its derivative to a new
vessel requires meticulous care to maintain specimen iden-
tity and integrity.119,120 Barcodes facilitate labeling and
tracking throughout the many stages of testing.120,121 Ro-
botic instruments should be programmed tominimize risk of
carryover or aerosolization, and each instrument undergoes
regular maintenance and is checked regularly for its perfor-
mance. Data transfer requires a similarly scrupulous pro-
cess for maintaining its integrity.
Proficiency Testing
Formal proficiency surveys are offered for many individ-
ual RNA-based tests, such as hepatitis C viral load and
BCR-ABL1 quantification. The CAP’s Cytogenomic Mi-
croarray Survey is a model for interlaboratory comparison
of array-based data, although this particular survey chal-
lenges DNA-based, rather than RNA-based, microarray
services.122 Proficiency surveys are meant to do the fol-
lowing: i) periodically check assay performance, ii) serve
an educational function for laboratory members, and iii)
promote quality improvement by sharing information on
current methods.123–125 The CAP and the Association for
Molecular Pathology have many resources supporting
quality assurance and proficiency, including help in iden-
tifying another provider with whom to exchange speci-
mens. In addition to interlaboratory exchange programs
to check for comparable signatures or individual analytic
test results, an alternative assessment method is to rean-
alyze internal samples as if they were unknowns.126
On the Horizon
This article describes the many principles of laboratory
medicine that guide us in validating, implementing, and
maintaining RNA-based tests. Strategies are described
to check patient-specific and generic assay performance
at critical junctures during each multistep protocol. With
proper attention to assay design and quality assurance, it
is clear that RNA profiling provides robust, accurate, and
reproducible results that are powerful by virtue of the
number of analytes that are evaluated, the informative sig-natures reflecting disease status in meaningful new ways,
and the redundancy that boosts confidence in the findings.
On the horizon are full transcriptome sequencing technolo-
gies that are likely to bring greater precision for quantifying
RNA and characterizing splice variants.118
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